Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug

On Monday September 14th, biotech company Cassava Sciences announced that the company’s Alzheimer’s drug, sumifilam, showed positive results in treating Alzheimer’s patients in a phase 2 study. The data will be presented at H.C. Wainwright’s 22nd Annual Global Investment Conference.